Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 23, 2023 - Issue 8: Biosimilars
Submit an article Journal homepage
2,097
Views
0
CrossRef citations to date
0
Altmetric
Original Research

Randomized, double-blind, multicenter study to evaluate efficacy, safety, tolerability, and immunogenicity between AVT04 and the reference product ustekinumab in patients with moderate-to-severe chronic plaque psoriasis

Steven R Feldmana Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, USA;b Department of Dermatology, The University of Southern Denmark, Odense, DenmarkView further author information
,
Nataliya Reznichenkoc Military Hospital (Military Unit A3309) of Military-Medical Clinical Center of Eastern Region, Zaporizhzhia, UkraineView further author information
,
Fausto Bertid Alvotech Swiss AG, Zürich, SwitzerlandView further author information
,
Paul Duijzingsd Alvotech Swiss AG, Zürich, SwitzerlandView further author information
,
Ruth Ruffieuxd Alvotech Swiss AG, Zürich, SwitzerlandView further author information
,
Hendrik Ottoe Clinical and Medical Affairs, Alvotech Germany GmbH, Jülich, GermanyView further author information
,
Halimu N Haliduolae Clinical and Medical Affairs, Alvotech Germany GmbH, Jülich, GermanyView further author information
,
Steffen Leutze Clinical and Medical Affairs, Alvotech Germany GmbH, Jülich, GermanyView further author information
&
Heimo Stroissnige Clinical and Medical Affairs, Alvotech Germany GmbH, Jülich, GermanyCorrespondence[email protected]
View further author information
 show all
Pages 759-771 | Received 05 Jun 2023, Accepted 07 Jul 2023, Published online: 12 Jul 2023

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.